Subsidiary's Mehsana facility awarded PIC/S GMP certification by Ukraine's SMDC
Senores Pharmaceuticals' subsidiary Ratnatris Pharmaceuticals' Mehsana (Gujarat) facility has been awarded PIC/S GMP certification by Ukraine's State Service on Medicines and Drugs Control ✅ The company says this expands its pathway to.
By ScoutQuest · · 1 min read
- Certification
- PIC/S GMP certification awarded to Mehsana (Gujarat) facility
- Issuing authority
- State Service of Ukraine on Medicines and Drugs Control (SMDC)
- Certificate dates
- Issued November 16, 2026; received by the company November 17, 2026
What was announced
- Senores Pharmaceuticals' subsidiary, Ratnatris Pharmaceuticals Private Limited, operates a manufacturing facility at Mehsana, Gujarat.
- That facility has been awarded PIC/S (Pharmaceutical Inspection Co-operation Scheme) Good Manufacturing Practices (GMP) certification.
- The certificate of GMP compliance was issued by the State Service of Ukraine on Medicines and Drugs Control (SMDC).
- It was issued on November 16, 2026 and received by the company on November 17, 2026.
What the company says it means
PIC/S GMP certification is a recognised manufacturing quality standard in the pharmaceutical sector. According to the update, the certification gives the company, through its subsidiary, an expanded pathway to pursue regulatory approvals across semi-regulated markets.
How to read this
- The announcement is about a certification of a manufacturing site, not about a product approval, an order or a sales contract.
- The stated benefit is the opening up of a route to apply for regulatory approvals in semi-regulated markets; the update points to the pathway rather than to any approval already obtained.
- The certificate relates to the subsidiary's Mehsana facility, so any future commercial gain would flow through that subsidiary.
Disclosure route
The company shared the update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and asked the exchanges to take it on record.
What to watch
Whether the company reports specific regulatory approvals or market entries that follow from this certification would be the next thing to track, since the certification itself is a gateway rather than a commercial outcome.
Also from Senores Pharmaceuticals
Q2 & H1FY27 call transcript: management reaffirms FY27 growth guidance
5 Nov 2026
Senores Pharmaceuticals files audio recording of Q2 & H1FY27 earnings conference call held October 29, 2026
29 Oct 2026
Monitoring agency report: nil deviation from IPO objects, after objects and timelines were revised
29 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.